{
  "documentMetadata": {
    "title": "Management of COVID-19",
    "lastUpdated": "2025-04-28",
    "sourceFile": "COVID-19, Inpatient Therapy.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Initial Clinical Evaluation"
    },
    {
      "type": "list",
      "items": [
        "Symptomatic person with positive test result (PCR or antigen)",
        "PCR much more sensitive than rapid (antigen) home test (using positive PCR as reference): MMWR 73(16) 365, 2024.",
        "Sensitivity of Antigen Tests: 47%. (peak positivity day 3 after onset of symptoms)",
        "Sensitivity of Viral Culture: 80% (peak positivity 2 days after onset of symptoms)",
        "Sensitivity of both tests better in presence of fever: 77% and 94%, antigen and culture, respectively",
        "Initial clinical evaluation focuses on:",
        "Date of onset of symptoms, not date of first positive test (to determine duration of illness and timing of treatment)",
        "Risk factors for development of severe disease",
        "Age > 65 years",
        "immune-compromised state",
        "obesity (BMI >35)",
        "diabetes mellitus",
        "chronic kidney disease",
        "Potential treatment-limiting organ dysfunction (renal, hepatic)",
        "Severity of disease (see table below)",
        "Child or adolescent, see also MIS-C / MIS-A",
        "General Refs: N Engl J Med 2020;382:1708; Lancet 2020;395:497; JAMA 2020;323:1061; JAMA 2020;323:1239."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Current Variants"
    },
    {
      "type": "list",
      "items": [
        "Omicron variants",
        "For most recent variant information, See CDC website.",
        "Getting the Omicron-specific monovalent Vaccine (XBB) provides neutralizing activity against all Omicron and subtypes",
        "Omicron variants are NOT neutralized by most of the available monoclonal antibodies, including:",
        "Neither Bebtelovimab, Sotrovimab, (casirivimab + imdevimab), nor (bamlanivimab + etesevimab) monoclonal antibody preparations work against the newer variants and should NOT be used.",
        "Pemivibart (Pemgarda) is a monoclonal antibody, used for primary prophylaxis, that has activity against Omicron variants."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Severity of Disease"
    },
    {
      "type": "table",
      "tableData": {
        "headers": ["Severity", "Indicators"],
        "rows": [
          ["Asymptomatic", "No symptoms"],
          ["Mild disease", "Fever, cough, sore throat, N/V, diarrhea, loss of taste or smell but no dyspnea; normal O2 saturation and normal chest X-ray"],
          ["Moderate disease", "Symptoms of mild disease plus evidence of lower respiratory tract infection (exam and/or imaging), O2 saturation 94% on room air"],
          ["Severe disease", "Symptoms of moderate disease but O2 saturation <94%, PaO2/FiO2 <300 mmHg, respiratory frequency >30 breaths per minute, or lung infiltrates >50%"],
          ["Critical disease", "Symptoms of severe disease but intubated with respiratory failure, septic shock, and/or multiorgan dysfunction"]
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Treatment"
    },
    {
      "type": "header",
      "level": 2,
      "text": "General Principles of Therapy"
    },
    {
      "type": "list",
      "items": [
        "Early diagnosis of COVID-19",
        "Important note: date of onset of first symptoms drives treatment decision making (not the date of first positive test).",
        "Two stages of disease:",
        "Day 1-7: active viral replication",
        "Antiviral therapies most likely to be efficacious at this early stage",
        "E.g., Remdesivir and oral direct-acting antiviral agents",
        "Start antiviral therapy as early as possible for maximal effect",
        "Day 7 - 14",
        "Antiviral therapies less effective, and maybe ineffective, in this stage of the disease",
        "Corticosteroids and other immune modulators are beneficial for those with severe disease"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Recommendations Based on Disease Severity"
    },
    {
      "type": "crossReference",
      "referenceData": {
        "text": "See Recommended Regimens, Dosing below for dosing / indications, see also the drug pages.",
        "targetType": "internalDocument",
        "targetIdentifier": "Recommended Regimens, Dosing"
      }
    },
    {
      "type": "table",
      "tableData": {
        "headers": ["Setting, disease severity, risk of progression", "Therapy"],
        "rows": [
          ["Hospitalized, mild disease (no lower respiratory tract disease). Patient at high risk of disease progression", "Remdesivir (see below for dosing)"],
          ["", "Dexamethasone"],
          ["", "Prophylactic anticoagulation (see below)"],
          ["Hospitalized, moderate disease (evidence of lower respiratory tract disease) with no supplemental O2 requirement. Patient at high risk of disease progression.", "Remdesivir"],
          ["", "Dexamethasone"],
          ["", "Prophylactic anticoagulation (see below)"],
          ["Hospitalized, severe disease (O2 saturation <94% and/or PaO2/FiO2 <300) requires supplemental O2.", "Remdesivir + Dexamethasone + Tocilizumab"],
          ["", "Baricitinib if hospitalized, not on mechanical ventilation or ECMO, and with severe and critical disease; ideally administered within the first 72h of hospitalization"],
          ["", "Therapeutic anticoagulation: For nonpregnant patients with D-dimer levels >ULN who are not at increased bleeding risk, and do not require high-flow oxygen or ICU-level care (for details see Anticoagulation below)"],
          ["", "For all others: Prophylactic anticoagulation (for details see Anticoagulation below)"],
          ["Hospitalized, critical disease -- requires mechanical ventilation or ECMO", "Dexamethasone + Remdesivir + Tocilizumab"],
          ["", "Vilobelimab can be added to existing therapeutic regimen for those within 2 days of initiation of Mechanical Ventilation or ECMO."],
          ["", "Prophylactic anticoagulation (for details see Anticoagulation below)"]
        ]
      }
    },
    {
      "type": "list",
      "items": [
        "Adjunctive therapy with acetaminophen, ibuprofen (or naproxen), guaifenesin, ondansetron, Imodium, inhaled albuterol, inhaled steroid, H2 blocker, and / or sleeping meds (e.g., melatonin) as needed prn",
        "Prophylactic dose anticoagulation with heparin is recommended for hospitalized patients with mild or moderate disease or for those with critical disease disease requiring mechanical ventilation or ECMO. Use of therapeutic anticoagulation with heparin for non-pregnant patients with severe disease requiring supplemental oxygen and elevated D-dimer (> ULN). See Anticoagulation below for details)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Recommended Regimens, Dosing"
    },
    {
      "type": "table",
      "tableData": {
        "headers": ["Type", "Drug", "Dose/duration", "Indication"],
        "rows": [
          ["Antiviral", "Remdesivir", "Adult (wt > 40 kg): 200 mg IV loading dose on day 1, then 100 mg IV daily maintenance dose. Infuse each dose over 30-120 min.\nPediatric (wt 3.5 - 40 kg): 5 mg/kg loading dose on day 1, then 2.5 mg/kg maintenance dose\nDuration: 5 days if not on ventilation/ECMO. If no clinical improvement at 5 days, extend to 10 days. 10 days for patients on mechanical ventilation/ECMO", "Hospitalized patients with disease.\nCan be used as 3 day course among those with mild to moderate disease."],
          ["Anti-inflammatory", "Dexamethasone", "6 mg once daily IV or po x 10 days for patients on supplemental oxygen or mechanical ventilation", "Hospitalized patients with severe and critical disease"],
          ["Anti-inflammatory (IL-6 inhibitor)", "Tocilizumab", "8 mg/kg, actual body weight up to 800 mg, as a single IV infusion with a second dose 12-24h later if no improvement", "Hospitalized patient with progressive severe or critical disease; RECOVERY trial systemic inflammation, e.g. CRP > 75 mg/L, as a criteria"],
          ["Anti-inflammatory (JAK inhibitor)", "Baricitinib", "4 mg po daily (for up to 14 days) + Remdesivir 200 mg on day 1, then 100 mg IV daily for up to 10 days + dexamethasone.\nFully approved by US FDA", "Hospitalized patients not on mechanical ventilation or ECMO with severe and critical disease; ideally administered within 72h of hospitalization"],
          ["Anti-inflammatory (JAK inhibitor)", "Tofacitinib", "10 mg po q12h (for up to 14 days) + Remdesivir 200 mg on day 1, then 100 mg IV daily for up to 10 days + Dexamethasone", "Hospitalized patients not on mechanical ventilation or ECMO with severe and critical disease; ideally administered within 72h of hospitalization"],
          ["Anti-inflammatory (Anti-Complement Factor 5a; anti-C5a)", "Vilobelimab", "800 mg IV (for minimum of Six doses) administered on Day 1, 2, 4, 8, 15 and 22", "Hospitalized, critically-ill patients within 48 hours of initiation of mechanical ventilation or ECMO"]
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Suggested Laboratory Evaluation, Inpatient"
    },
    {
      "type": "table",
      "tableData": {
        "headers": ["When", "What to order"],
        "rows": [
          ["At hospital admission", "
CBC with differential, troponin, LFTs, Chem 10, CPK\n
Ferritin, CRP, LDH, d-dimer, PT/PTT/fibrinogen\n
For risk stratification (repeat if patient deteriorates clinically):\n  
LDH (repeat daily if elevated)\n  
Troponin\n  
Baseline EKG\n
Viral serologies (unless checked recently):\n  
HIV\n  
HCV antibody\n  
HBV surface antibody, core antibody and surface antigen\n
If clinically indicated:\n  
Blood cultures x 2, sputum culture(BAL recommended by some), UA with reflex to culture, and Urine strep/legionella antigen\n  
B-HCG for women of childbearing age"],
          ["Recommended daily labs (until stable)", "
CBC with diff (esp. total lymphocyte count)\n
Complete metabolic panel\n
CPK (creatine kinase)\n
CRP first week of hospitalization; inflammatory markers hard to interpret beyond 1 week"],
          ["Recommended every other day (daily if elevated or pt in ICU)", "
PT/PTT/fibrinogen\n
D-dimer"],
          ["Radiology", "
Portable chest x-ray at admission; further imaging based on evaluation, concern for secondary bacterial infection, pulmonary embolism, etc."]
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Laboratory Predictors: Severe Disease, Poor Outcome"
    },
    {
      "type": "list",
      "items": [
        "Decreased absolute lymphocyte count",
        "Ratio of absolute neutrophil count to absolute lymphocyte count > 3.5",
        "Elevated CPK, CRP, Ferritin, D-dimer, LDH, Troponin, PT",
        "Thrombocytopenia",
        "LFTs 5x upper limit of normal",
        "Acute kidney injury",
        "See Lancet 2020;395:1054"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Concomitant bacterial pneumonia is uncommon on admission (Am J Respir Crit Care Med. 2021;204: 921)",
        "Hence, routine empiric coverage for bacterial co-infection is not recommended",
        "Hospitalized patients with COVID-19 pneumonia may develop bacterial and fungal pneumonia in the health care setting",
        "Overall bacterial infection rate of 7.1% with 3.5% of patients infected at presentation and with 15.5% of patients developing secondary bacterial infections over the course of illness (Clin Microbiol Infect 220; Jul 22;S1198-743X(20)30423-7)",
        "Single center study of 4267 hospitalized patients in New York City between 3/1/20 to 4/28/20 (Infect Control Hosp Epidemiol 2020; Jul 24, 1-13. doi: 10.1017/ice.2020.368) found overall bacterial and fungal infection rate of 3.6% with respiratory only infection in 46%, blood only in 40%, both in 14%. 95% of patients with positive respiratory cultures were intubated. Similar findings in a second multicenter study (Open Forum Infect Dis. 2020 Dec 21;8(1):ofaa578)."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "header",
      "level": 2,
      "text": "Therapies: Not Recommended"
    },
    {
      "type": "list",
      "items": [
        "IL-1 inhibitors: Efficacy unproven, not recommended outside of a clinical trial.",
        "Convalescent plasma: no proven benefit.",
        "Not recommended for use in hospitalized immunocompetent persons; insufficient evidence on which to base any recommendation for immunocompromised persons.",
        "Colchicine: Efficacy unproven",
        "Randomized placebo controlled trial (not peer reviewed, pre-print in medRXiv) of non-hospitalized patients with proven or suspected COVID-19 found no statistically significant difference in the primary efficacy composite endpoint of death or hospitalization for COVID-19 in the primary analysis population, with possible benefit (4.6% vs. 6%) in a subpopulation analysis of those who tested PCR-positive for COVID-19.",
        "Interferon beta 1-a: Efficacy unknown, not recommended outside of a clinical trial.",
        "Ivermectin: Not Recommended",
        "No efficacy observed in 4 large randomized trials. (Jama. 325, 1426, 2021; BMC Infectious Diseases.21(1):635, 2021; N Engl J Med 2022 Mar 30; JAMA 329:888, 2023). The latter study used higher-doses of ivermectin (600 ug/kg), which was advocated by those who claimed a therapeutic benefit of ivermectin despite no evidence in clinical trials using lower doses. This study randomized 1206 participants with mild to moderate symptoms of COVID. The time to symptom recovery was identical among high-dose ivermectin recipients and placebo recipients (11 days in each group). Combined hospitalizations, deaths and ER visits were no different (34 ivermectin, 36 placebo; HR 1.0) and 1 patient in the ivermectin group died vs 0 in the placebo group.",
        "Manufacturing company (Merck) recommends against using ivermectin for treatment of COVID-19 disease",
        "Chloroquine or Hydroxychloroquine + Azithromycin: Not recommended in any setting due to lack of efficacy and risk of serious, potentially fatal cardiac arrhythmia",
        "HIV protease inhibitors: Not recommended, clinical benefit not demonstrated"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Anticoagulation"
    },
    {
      "type": "list",
      "items": [
        "COVID-19 infection is associated with a hypercoagulable state. Results from several large studies comparing prophylactic to therapeutic anticoagulation suggest benefit of therapeutic anticoagulation in patients with moderate but not severe infection. Patients hospitalized for COVID-19 who require supplemental oxygen but not high-flow nasal cannula or ventilatory support are more likely to survive to discharge without requiring organ support with therapeutic compared to prophylactic heparin. Overall survival was not improved with therapeutic compared to prophylactic heparin. Severely ill patients (e.g., ICU level care, high-flow oxygen) do not benefit from therapeutic anticoagulation and may be harmed by bleeding risks. References: N Engl J Med. 2021;385:790-802 and N Engl J Med. 2021; 385:777-789). Link to NIH guidelines here.",
        "Prophylactic heparin-based anticoagulation",
        "Dosing: sub-cutaneous heparin or enoxaparin for standard venous thromboembolism (VTE) prophylaxis",
        "Recommended for:",
        "Patients with no requirement for supplemental oxygen or who are hospitalized for reasons other than COVID-19.",
        "Patients who require supplemental oxygen but patient or provider preference for prophylactic rather than therapeutic dosing, for example if risk of bleeding outweighs the benefit.",
        "Patients who require non-invasive positive-pressure ventilation, oxygen therapy >20L, or ICU-level care",
        "Contraindications:",
        "Any contraindication to therapeutic or prophylactic anticoagulation, such as active CNS bleed, severe thrombocytopenia with platelet count < 25,000, history of heparin-induced thrombocytopenia",
        "Therapeutic heparin-based anticoagulation",
        "Dosing: Standard VTE treatment dosing of heparin-based anticoagulation should be used, continued for no more than 14 days and discontinued on discharge.",
        "Enoxaparin is preferable to unfractionated heparin unless CrCl < 15 or other contraindication.",
        "Decreasing to prophylactic dose may be considered with resolving clinical course (e.g. discontinuation of oxygen) or if clinical severity increases to ICU level support or oxygen >20L at the discretion of the provider given lack of clear data in this area.",
        "For patients already on chronic full dose anticoagulation (e.g. DOAC, warfarin), this may be continued instead of heparin-based anticoagulation",
        "Recommended for",
        "Non-critically ill patients requiring supplemental oxygen or stable/improving HFNC < 20L. Note: the decision to initiate therapeutic versus prophylactic anticoagulation, must weigh potential benefits with risks and patient preference.",
        "Potential benefits: decreased need for organ support but no difference in survival",
        "Potential risks: bleeding complications",
        "Contraindications:",
        "Any contraindication to heparin or therapeutic anticoagulation, such as dual antiplatelet therapy, major bleeding with the last 30 days, known acquired or inherited bleeding disorder, history of heparin induced thrombocytopenia, recent ischemic stroke, platelet count < 50 x 10^9/L, Hemoglobin < 8 g/dL, or clinical discretion of the treating physician.",
        "See also, COVID-19 Transmission, Exposure, Isolation."
      ]
    }
  ]
}
